Emerging Nonopioid Analgesic Strategies in Total Joint Arthroplasty: Mechanisms, Evidence, and Practical Implementation.

BACKGROUND: Total joint arthroplasty (TJA), encompassing total hip and knee arthroplasty, remains one of the most effective procedures for end-stage arthritis, but is frequently associated with substantial postoperative pain. Opioid-based analgesia, although effective, carries risks of dependence, respiratory depression, and delayed recovery. In response to the opioid crisis, multimodal nonopioid strategies have gained prominence to improve outcomes while minimizing adverse effects.

METHODS: This review summarized current and emerging nonopioid analgesic modalities with clinical relevance to TJA. Recent randomized controlled trials, meta-analyses, and regulatory updates were analyzed to evaluate efficacy, safety, and practical integration into perioperative care.

RESULTS: Novel pharmacologic options-including suzetrigine (VX-548), a selective voltage-gated sodium 1.8 sodium channel blocker; intravenous meloxicam, a parenteral COX-2 inhibitor; and extended-release liposomal bupivacaine, demonstrate meaningful opioid-sparing effects with favorable tolerability profiles. Adjunctive nonpharmacologic modalities such as transcutaneous electrical nerve stimulation, sustained-acoustic-medicine ultrasound, and acupuncture offer complementary benefits by modulating peripheral and central sensitization. In addition, injectable hydrogel and polymer-based delivery systems represent a next generation of sustained local analgesia with the potential to extend pain control beyond 72 hours. The Non-Opioids Prevent Addiction in the Nation Act, implemented in 2025, expands Medicare reimbursement for nonopioid pain treatments, providing a key policy incentive for adoption in surgical care.

CONCLUSIONS: Multimodal, opioid-sparing regimens that incorporate both pharmacologic and nonpharmacologic agents offer the most balanced approach to pain management after TJA. Although promising, wider implementation is limited by cost, access, and a paucity of arthroplasty-specific trials. Future directions include integration of artificial intelligence to individualize regimens, use of predictive pain algorithms, and real-time physiologic pain monitoring. Broader clinical validation and economic analyses are essential to establish sustainable, patient-centered models of postoperative pain control.